CRVS Corvus Pharmaceuticals

Corvus Pharmaceuticals to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference

Corvus Pharmaceuticals to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference

SOUTH SAN FRANCISCO, Calif., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that members of its leadership team will conduct one-on-one meetings with investors and participate in a fireside chat presentation at the Guggenheim 2nd Annual Healthcare Innovation Conference, which is being held in Boston, MA. The fireside chat will be on Monday, November 10, 2025 at 8:30 am ET. 

A webcast of the fireside chat will be available live and for 90 days following the event. The webcast may be accessed via the section of the Corvus website. 

About Corvus Pharmaceuticals 

Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company pioneering the development of ITK inhibition as a new approach to immunotherapy for a broad range of cancer and immune diseases. The Company’s lead product candidate is soquelitinib, an investigational, oral, small molecule drug that selectively inhibits ITK. Its other clinical-stage candidates are being developed for a variety of cancer indications. For more information, visit . 

INVESTOR CONTACT: 

Leiv Lea 

Chief Financial Officer 

Corvus Pharmaceuticals, Inc. 

 

  

MEDIA CONTACT: 

Sheryl Seapy 

Real Chemistry 



EN
31/10/2025

Underlying

CRVSCorvus Pharmaceuticals

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Corvus Pharmaceuticals

 PRESS RELEASE
Free
CRVS Corvus Pharmace...

Corvus Pharmaceuticals Presents Final Data from Soquelitinib Phase 1/1...

Corvus Pharmaceuticals Presents Final Data from Soquelitinib Phase 1/1b T Cell Lymphoma Trial Patients in 200 mg BID cohort had median progression free survival of 6.2 months and median overall survival of 28.1 months, comparing favorably to results with other therapies Data supports ongoing registration Phase 3 trial in r/r PTCL, Phase 1 trial in atopic dermatitis and potential expansion into other immune and inflammatory diseases Highlights ITK inhibition novel mechanism of action affecting T cell receptor signaling and T cell differentiation Presented in an oral session at the 67th A...

December 8, 2025 1 EN
 PRESS RELEASE
Free
CRVS Corvus Pharmace...

Corvus Pharmaceuticals Provides Business Update and Reports Third Quar...

Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2025 Financial Results Completed enrollment in soquelitinib atopic dermatitis Phase 1 trial extension cohort 4 (200 mg BID dose with 8-week treatment period) with data announcement anticipated in January Soquelitinib atopic dermatitis phase 2 trial on track to initiate in early Q1 2026 Phase 3 registrational clinical trial of soquelitinib in relapsed/refractory peripheral T cell lymphoma (PTCL) enrolling with multiple clinical sites open; final Phase 1/1b results accepted for oral presentation at the American Societ...

November 4, 2025 1 EN
 PRESS RELEASE
Free
CRVS Corvus Pharmace...

Corvus Pharmaceuticals to Present Final Data from Soquelitinib Phase 1...

Corvus Pharmaceuticals to Present Final Data from Soquelitinib Phase 1/1b T Cell Lymphoma Trial at the 67th American Society of Hematology Annual Meeting & Exposition SOUTH SAN FRANCISCO, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that final data from its Phase 1/1b trial of soquelitinib in patients with T cell lymphoma will be presented in an oral session at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition, which is taking place December 6-9, 2025 in Orlando, F...

November 3, 2025 1 EN
 PRESS RELEASE
Free
CRVS Corvus Pharmace...

Corvus Pharmaceuticals to Present at the Guggenheim 2nd Annual Healthc...

Corvus Pharmaceuticals to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference SOUTH SAN FRANCISCO, Calif., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that members of its leadership team will conduct one-on-one meetings with investors and participate in a fireside chat presentation at the Guggenheim 2nd Annual Healthcare Innovation Conference, which is being held in Boston, MA. The fireside chat will be on Monday, November 10, 2025 at 8:30 am ET.  A webcast of the fireside cha...

October 31, 2025 1 EN
 PRESS RELEASE
Free
CRVS Corvus Pharmace...

Corvus Pharmaceuticals to Provide Business Update and Third Quarter 20...

Corvus Pharmaceuticals to Provide Business Update and Third Quarter 2025 Financial Results on November 4, 2025 Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT SOUTH SAN FRANCISCO, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the company will host a conference call and webcast on November 4, 2025 at 4:30 pm ET (1:30 pm PT) to provide a business update and report third quarter 2025 financial results.   The conference call can be accessed by dialing 1-800-717-1...

October 28, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch